LUNGevity: Lung Cancer Stigma Community Based Participatory Research
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06286592 |
Recruitment Status :
Not yet recruiting
First Posted : February 29, 2024
Last Update Posted : March 29, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lung Cancer | Behavioral: Ultra-brief mindfulness intervention video Behavioral: Forgiveness video Behavioral: ACT values video | Not Applicable |
Lung cancer is the deadliest form of cancer, with the five year survival rate being 18.6%. Survival rates are even lower for intersectional underserved groups. Stigma about having lung cancer is very common, with 95% of lung cancer patients reporting lung cancer stigma. Stigma leads to higher rates of depressive symptoms, lower disclosure of smoking, lower likelihood of engaging with smoking cessation services, and decreased likelihood of following through on treatment recommendations. Lung cancer stigma and intersectional stigma related to minoritized group status leads to increased morbidity and mortality and health disparities. Mindfulness interventions have been shown to decrease stigma and the negative impacts of stigma, however, these interventions have never been tested to decrease lung cancer stigma specifically.
In this study, the investigators propose an innovative Multiphase Optimization Strategy (MOST) methodology to build and optimize a brief virtual mindfulness intervention to decrease lung cancer stigma. Using an innovative approach that combines Community Based Participatory Research (CBPR) and MOST, the investigators will first build a diverse coalition of lung cancer patients on a participatory action council per CBPR best practice models, with community members as equal stakeholders and part of the research team at every stage of the project. This study aims to:
Test mindfulness intervention components for lung cancer stigma in lung cancer patients to improve lung cancer treatment outcomes (i.e., patient-provider communication, willingness to accept referral to tobacco cessation, and quit rates).
Assess preliminary efficacy of these interventions on lung cancer stigma among lung cancer patients by race, ethnicity and sexual/gender classification.
Explore reach, acceptability and satisfaction of a mindfulness intervention to address lung cancer stigma, with a focus reaching patients in underserved groups (Black, Latinx, LGBTQ+ individuals, and low SES) in order to decrease health disparities and extend the five year survival rate.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Intervention Model Description: | Details of the specific interventions will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | CBPR Intervention to Decrease Lung Cancer Stigma and Health Disparities (LUNGevity Lung Cancer Stigma Reduction) |
Estimated Study Start Date : | March 2024 |
Estimated Primary Completion Date : | November 2025 |
Estimated Study Completion Date : | November 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Conditions 1, 2 & 3
Condition 1 = Brief Mindfulness Video Condition 2 = Forgiveness Video Condition 3 = ACT Video *Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Behavioral: Ultra-brief mindfulness intervention video
Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. Behavioral: Forgiveness video Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. Behavioral: ACT values video Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Experimental: Conditions 1 & 2
Condition 1 = Brief Mindfulness Video Condition 2 = Forgiveness Video *Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Behavioral: Ultra-brief mindfulness intervention video
Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. Behavioral: Forgiveness video Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Experimental: Condition 1
Condition 1 = Brief Mindfulness Video *Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Behavioral: Ultra-brief mindfulness intervention video
Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Experimental: Conditions 1 & 3
Condition 1 = Brief Mindfulness Video Condition 3 = ACT Video *Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Behavioral: Ultra-brief mindfulness intervention video
Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. Behavioral: ACT values video Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Experimental: Conditions 2 & 3
Condition 2 = Forgiveness Video Condition 3 = ACT Video *Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Behavioral: Forgiveness video
Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. Behavioral: ACT values video Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Experimental: Condition 2
Condition 2 = Forgiveness Video *Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Behavioral: Forgiveness video
Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Experimental: Condition 3
Condition 3 = ACT Video *Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
Behavioral: ACT values video
Details of the specific intervention will be selected in collaboration with the Community Advisory Board. Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board. |
No Intervention: No Intervention
Treatment as usual.
|
- Lung Cancer Stigma Inventory (LCSI) [ Time Frame: 1 year ]Both perceived/felt stigma (negative appraisal and devaluation from others) and internalized/self (internalization of perceived stigma) stigma from having lunch cancer.
- Tobacco use quit likelihood [ Time Frame: 1 year ]If current smoker, assessing subjectively reported quit likelihood on a 0 (meaning not likely) to 10 (meaning extremely likely) scale.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participants must be patients 18 years of age or older with a history of tobacco use to qualify for study inclusion. At least a portion of the participants will also need to be current lung cancer patients. Participants must be able to read and understand English and have normal to corrected vision and hearing.
- For the Community Advisory Board (CAB), participants must have been diagnosed with lung cancer, be at least 18 years of age or older, and self-identify as being part of an underrepresented group identity.
Exclusion Criteria:
- Any potential participants who do not meet the above inclusion criteria will be excluded from the study.
- Patients who are under the age of 18 and who do not have a history of tobacco use will be excluded from participating in the study.
- Individuals who cannot read or understand English or who do not have normal to corrected vision and hearing will be excluded from the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06286592
Contact: Kristen E Riley, PhD | 484-459-2004 | kristen.riley@rutgers.edu |
Principal Investigator: | Kristen E Riley, PhD | Rutgers, The State University of New Jersey |
Publications of Results:
Other Publications:
Responsible Party: | Kristen E. Riley, Ph.D., Assistant Professor, Clinical Psychology Department, Rutgers, The State University of New Jersey |
ClinicalTrials.gov Identifier: | NCT06286592 |
Other Study ID Numbers: |
Pro2023002053 |
First Posted: | February 29, 2024 Key Record Dates |
Last Update Posted: | March 29, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Participant age range and status collected during trial will be reported after deidentification. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) |
Time Frame: | Immediately following publication. No end date. |
Access Criteria: | Anyone who wishes to access the data. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
community-based participatory research community advisory board stimga cancer smoking cessation |
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases |